Get the Stockscreener App
32.99
6.76%
-2.39
After Hours:
32.50
-0.49
-1.49%
Metsera Inc stock is traded at $32.99, with a volume of 1.89M.
It is down -6.76% in the last 24 hours and up +15.96% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$35.38
Open:
$35.78
24h Volume:
1.89M
Relative Volume:
1.91
Market Cap:
$3.47B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.81%
1M Performance:
+15.96%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$32.40
$36.24
1-Week Range:
$32.40
$40.95
52-Week Range:
$12.30
$47.40
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
32.99 | 3.72B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
We're Hopeful That Metsera (NASDAQ:MTSR) Will Use Its Cash Wisely - Yahoo Finance
Metsera stock rating reiterated by Cantor Fitzgerald ahead of key updates - Investing.com Australia
Metsera, Inc. Poised for Growth: Anticipated Catalysts and Clinical Trial Success Drive Buy Rating - TipRanks
Why is Metsera Inc. stock attracting strong analyst attentionGet timely alerts on top market movers - jammulinksnews.com
What makes Metsera Inc. stock price move sharplyBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Metsera reports Q2 EPS (66c), consensus (68c) - TipRanks
Metsera Posts Narrower Q2 Loss - MarketScreener
Metsera shares tumble as quarterly loss worse than expected By Investing.com - Investing.com Nigeria
Metsera shares tumble as quarterly loss worse than expected - Investing.com
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress - GlobeNewswire
What are the latest earnings results for Metsera Inc.Unlock your portfolio’s full growth potential - jammulinksnews.com
Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why - Yahoo Finance
What is Metsera Inc. company’s growth strategyAccess high-quality stock research instantly - jammulinksnews.com
Chartists Watching For Breakout in Metsera Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Should I hold or sell Metsera Inc. stock in 2025Stock Market Review That Work - jammulinksnews.com
What are analysts’ price targets for Metsera Inc. in the next 12 monthsGet daily expert analysis for smarter investing - jammulinksnews.com
What is the dividend policy of Metsera Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
Does Metsera Inc. stock perform well during market downturnsUnmatched market performance - jammulinksnews.com
Is Metsera Inc. a growth stock or a value stockDiscover undervalued opportunities early - jammulinksnews.com
How strong is Metsera Inc. company’s balance sheetUnlock daily stock market insights for success - jammulinksnews.com
What institutional investors are buying Metsera Inc. stockCapitalize on high-yield stock opportunities - jammulinksnews.com
Why Metsera Inc. stock is on top investor watchlistsSkyrocketing profit margins - jammulinksnews.com
What drives Metsera Inc. stock priceFree Buy/Sell Signal Notifications - PrintWeekIndia
How high can Metsera Inc. stock price go in 2025Breakthrough profit margins - jammulinksnews.com
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - MSN
Is Metsera Inc. stock a growth or value playExceptional ROI - jammulinksnews.com
What analysts say about Metsera Inc. stockSuperior risk-adjusted returns - Autocar Professional
Metsera Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Is Metsera Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):